Editas Medicine, Inc.
NASDAQ:EDITBiotechnology
+$0.07 today
- Market cap
- $281.67M
- Beta
- 2.10
- P/E (TTM)
- -2.4
- EPS (TTM)
- -$1.11
Volume 2.02M
Average 2.06M
Returns on capital
Editas Medicine, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-586.6%
avg -97.5%
ROIC
-65.6%
avg -42.2%
ROA
-85.8%
avg -41.2%
Analysis
ROIC is currently the strongest return metric at -65.6% versus its period average of -42.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Gilmore O'Neill | President, Chief Executive Officer & Director | USD 1.07M | 62 | — | — |
Linda C. Burkly | Executive Vice President & Chief Scientific Officer | USD 734.97K | 69 | — | — |
Amy Parison | Senior Vice President & Chief Financial Officer | USD 555.52K | 40 | 13.84K | 0.01% |
Feng Zhang | Co-Founder & Scientific Advisory Board Member | — | — | 125.00K | 0.13% |
George McDonald Church | Co-Founder & Scientific Advisory Board Member | — | 72 | — | — |
Damien Grierson | Senior Vice President, General Counsel & Corporate Secretary | — | — | — | — |
Frank Panaccio | Senior Vice President & Chief Business Officer | — | — | — | — |
Gregory Whitehead | Executive Vice President and Chief Technical & Quality Officer | — | — | — | — |
Tom Love | Vice President of People | — | — | — | — |
Brieana Buckley | Senior Vice President of Development and Program Leadership | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 3, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$176,721.87
Net Transaction Value
−$176,721.87
Net selling
Most Active
Burkly Linda
6 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 11, 26Nov 11, 2026 | O'Neill Gilmore Neil Direct | Sell | $51.1K$51,121.64 |
| Nov 11, 26Nov 11, 2026 | Burkly Linda Direct | Sell | $18.9K$18,874.72 |
| Sep 3, 26Sep 3, 2026 | Burkly Linda Direct | Sell | $2.2K$2,153.37 |
| Sep 3, 26Sep 3, 2026 | Parison Amy Direct | Sell | $1.4K$1,375.85 |
| Sep 3, 26Sep 3, 2026 | O'Neill Gilmore Neil Direct | Sell | $15.6K$15,562.61 |
| Aug 3, 26Aug 3, 2026 | Parison Amy Direct | Sell | $1.7K$1,749.24 |
| Jul 28, 26Jul 28, 2026 | Burkly Linda Direct | Sell | $13.2K$13,157.76 |
| Jun 3, 26Jun 3, 2026 | Parison Amy Direct | Sell | $1.3K$1,253.26 |
| Jun 3, 26Jun 3, 2026 | O'Neill Gilmore Neil Direct | Sell | $41.5K$41,542.92 |
| Jun 3, 26Jun 3, 2026 | Burkly Linda Direct | Sell | $2K$1,974.50 |
1–10 of 16
Summary
Insiders reported 0 buys worth $0.00 and 16 sells worth $176,721.87 over the last 12 months. That adds up to net selling of $176,721.87. Burkly Linda was the most active insider with 6 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +27.1% | -13.5% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +27.1% over three years. Forward estimates point to Revenue at -13.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Editas Medicine, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about EDIT's management, answered from reported figures.
Who manages EDIT?
Editas Medicine, Inc. (EDIT) lists 10 active executives. The top listed executive is Feng Zhang, Co-Founder & Scientific Advisory Board Member.
Are EDIT insiders buying or selling?
Recent insider activity shows net buying of $42.42M.
Continue the stock analysis
Jump to another research area for this company.